As the pharmaceutical industry faces pointed criticism over its patent practices, an effort appears to be under way to push back and challenge one of its leading critics in hopes of changing the narrative about patents and their role in prescription drug pricing.
The focus is on a nonprofit called the Initiative for Medicines, Access & Knowledge, or I-MAK, which has published several papers over the last few years criticizing drug makers for pursuing patents that may profitably extend the marketability of their medicines, but without necessarily adding any new, substantive value.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
